220 related articles for article (PubMed ID: 38560994)
1. Advancements and prospects of lipid-based nanoparticles: dual frontiers in cancer treatment and vaccine development.
Shaw I; Boafo GF; Ali YS; Liu Y; Mlambo R; Tan S; Chen C
J Microencapsul; 2024 May; 41(3):226-254. PubMed ID: 38560994
[TBL] [Abstract][Full Text] [Related]
2. Lipid-based Nanoparticles for the Targeted Delivery of Anticancer Drugs: A Review.
Khodaverdi H; Zeini MS; Moghaddam MM; Vazifedust S; Akbariqomi M; Tebyaniyan H
Curr Drug Deliv; 2022; 19(10):1012-1033. PubMed ID: 35078396
[TBL] [Abstract][Full Text] [Related]
3. Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy.
Zhang C; Ma Y; Zhang J; Kuo JC; Zhang Z; Xie H; Zhu J; Liu T
Molecules; 2022 Mar; 27(6):. PubMed ID: 35335310
[TBL] [Abstract][Full Text] [Related]
4. Recent advances and prospects for lipid-based nanoparticles as drug carriers in the treatment of human retinal diseases.
Zeng S; Chen Y; Zhou F; Zhang T; Fan X; Chrzanowski W; Gillies MC; Zhu L
Adv Drug Deliv Rev; 2023 Aug; 199():114965. PubMed ID: 37315899
[TBL] [Abstract][Full Text] [Related]
5. [The development of novel tumor targeting delivery strategy].
Gao HL; Jiang XG
Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
[TBL] [Abstract][Full Text] [Related]
6. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery.
Baeza A; Colilla M; Vallet-Regí M
Expert Opin Drug Deliv; 2015 Feb; 12(2):319-37. PubMed ID: 25421898
[TBL] [Abstract][Full Text] [Related]
7. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
8. Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment.
Zhao C; Zhu X; Tan J; Mei C; Cai X; Kong F
Biomed Pharmacother; 2024 Feb; 171():116113. PubMed ID: 38181717
[TBL] [Abstract][Full Text] [Related]
9. Passive and Active Drug Targeting: Role of Nanocarriers in Rational Design of Anticancer Formulations.
Das RP; Gandhi VV; Singh BG; Kunwar A
Curr Pharm Des; 2019; 25(28):3034-3056. PubMed ID: 31470779
[TBL] [Abstract][Full Text] [Related]
10. Lipid-based nanoparticles as drug delivery carriers for cancer therapy.
Waheed I; Ali A; Tabassum H; Khatoon N; Lai WF; Zhou X
Front Oncol; 2024; 14():1296091. PubMed ID: 38660132
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles for Cancer Targeting: Current and Future Directions.
Swain S; Sahu PK; Beg S; Babu SM
Curr Drug Deliv; 2016; 13(8):1290-1302. PubMed ID: 27411485
[TBL] [Abstract][Full Text] [Related]
12. Lipid-based nanoparticles for treatment of cancer.
Sheoran S; Arora S; Samsonraj R; Govindaiah P; Vuree S
Heliyon; 2022 May; 8(5):e09403. PubMed ID: 35663739
[TBL] [Abstract][Full Text] [Related]
13. Environmental stimulus-responsive mesoporous silica nanoparticles as anticancer drug delivery platforms.
Zhao H; Li Y; Chen J; Zhang J; Yang Q; Cui J; Shi A; Wu J
Colloids Surf B Biointerfaces; 2024 Feb; 234():113758. PubMed ID: 38241892
[TBL] [Abstract][Full Text] [Related]
14. Lipid‑based nanoparticles for the therapeutic delivery of non‑coding RNAs in breast cancer (Review).
Silva-Cázares MB; Saavedra-Leos MZ; Jordan-Alejandre E; Nuñez-Olvera SI; Cómpean-Martínez I; López-Camarillo C
Oncol Rep; 2020 Dec; 44(6):2353-2363. PubMed ID: 33125103
[TBL] [Abstract][Full Text] [Related]
15. Lipid-Based Nanoparticle Functionalization with Coiled-Coil Peptides for
Aschmann D; Knol RA; Kros A
Acc Chem Res; 2024 Apr; 57(8):1098-1110. PubMed ID: 38530194
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticles-mediated drug delivery approaches for cancer targeting: a review.
Sultana S; Khan MR; Kumar M; Kumar S; Ali M
J Drug Target; 2013 Feb; 21(2):107-25. PubMed ID: 22873288
[TBL] [Abstract][Full Text] [Related]
17. Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics.
Gajbhiye KR; Salve R; Narwade M; Sheikh A; Kesharwani P; Gajbhiye V
Mol Cancer; 2023 Oct; 22(1):160. PubMed ID: 37784179
[TBL] [Abstract][Full Text] [Related]
18. Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles.
Alavi M; Hamidi M
Drug Metab Pers Ther; 2019 Feb; 34(1):. PubMed ID: 30707682
[TBL] [Abstract][Full Text] [Related]
19. Use of Microfluidics to Prepare Lipid-Based Nanocarriers.
Vogelaar A; Marcotte S; Cheng J; Oluoch B; Zaro J
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111539
[TBL] [Abstract][Full Text] [Related]
20. Analytical characterization of liposomes and other lipid nanoparticles for drug delivery.
Fan Y; Marioli M; Zhang K
J Pharm Biomed Anal; 2021 Jan; 192():113642. PubMed ID: 33011580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
